Answers are grounded in this paper and cite their sources.
This study demonstrates nocathiacin's potent antibacterial efficacy against multidrug-resistant Gram-positive pathogens, indicating its clinical potential.
The extreme hydrophobicity of nocathiacin, a potent thiopeptide antibiotic against multidrug-resistant (MDR) Gram-positive pathogens, has limited its clinical development. This study formulated an injectable lyophilized nocathiacin with enhanced solubility (12.59 mg/mL). In vitro testing against 1050 clinical isolates demonstrated exceptional potency (MIC50: 0.0078–0.0156 mg/L; 64–128-fold lower than vancomycin/linezolid) and bactericidal activity (MBC50 = 4–16 × MIC). Murine systemic and localized infection models showed superior efficacy (ED50: 0.64–1.96 mg/kg; ~3 log (CFU/g) reduction in lung/thigh at 2/8 mg/kg). PK/PD analysis in immunocompromised mice identified AUC0–24/MIC and %T > MIC as primary efficacy drivers (R2 ≥ 0.97), indicating time-dependent killing. Favorable PK in rats/monkeys included moderate half-lives (4.7–5.5 h), biliary-dominated excretion (26.01% parent drug), minimal renal clearance (<0.10%), and no CYP inhibition/induction or significant transporter interactions. These results support injectable nocathiacin as a promising clinical candidate for MDR Gram-positive infections.
No takes yet. Share an insight, caveat, or question.
Xiong et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: